Background: Cancer-related neuropathic pain is sometimes unresponsive to multidrug treatment. Novel drugs are required to treat such severe pain without necessitating the use of adjuvant analgesics. Tapentadol is a new drug that has a dual mechanism as both an opioid agonist and noradrenalin reuptake inhibitor. The study objective was to investigate the effectiveness of oral tapentadol for relieving cancer-related neuropathic pain. Methods: A retrospective, single-center, open, non-randomized study was conducted at the Nagoya City University Hospital. The study included 38 Japanese patients with advanced cancer who received opioids, such as tramadol, oral oxycodone and transdermal fentanyl, with or without adjuvant analgesics. Eastern Cooperative Oncology Group performance status, Numerical Rating Scale, primary tumor type, primary opioid and tapentadol doses, adjuvant analgesic prescriptions, outcomes and adverse events of opioid switching were assessed for 7 days. Results: Eighteen (47.3%) out of 38 patients were enrolled in this study. The average performance status was 2.13 ± 0.94 (mean ± standard deviation). After switching to oral tapentadol, the pain score decreased from 3.78 to 2.78. The patients who had clinically improved effective pain scores had a higher percentage of prior opioid use for more than 2 months. After switching to tapentadol, adverse events were usually mild, with a grade of 1-2 by the Common Terminology Criteria for Adverse Events v4.03.
Introduction
Most cancer patients suffer from cancer-related pain, which includes neuropathic pain and nociceptive pain, and this pain is an important factor in determining a patient's quality of life (1) . The World Health Organization (WHO) recommends opioids to manage cancerrelated pain (2) . Although previous studies have demonstrated that opioids can reduce non-cancer-related neuropathic pain, opioids alone are not sufficient to reduce cancer-related neuropathic pain (3, 4) . Therefore, in many cases, neuropathic pain associated with cancer is treated with opioid analgesics and supplemental analgesics, such as antidepressants and anticonvulsants (5) .
Tapentadol was introduced in Japan in 2014 as an opioid with a new mechanism of action. It is indicated for moderate to severe cancer pain, like morphine and oxycodone. Tapentadol is an atypical opioid with a dual mechanism of action, targeting both opioid receptors and neurotransmitter reuptake (6) . It has an inhibitory action on the reuptake of noradrenaline, similar to that of certain antidepressants. Therefore, the efficacy of tapentadol to treat neuropathic pain is expected to be better than that of other opioids. However, tapentadol has no established clinical evidence for cancerrelated neuropathic pain. Therefore, it is not used as widely as oxycodone preparations.
There is no clear standard for the use of tapentadol or the use of other opioid analgesics. We conducted this retrospective study to investigate the effectiveness of opioid switching to oral tapentadol for relieving cancer-related neuropathic pain in patients of a Japanese palliative care ward.
Patients and methods

Trial design
This retrospective, single-center, open, non-randomized study was conducted at the Nagoya City University Hospital. It was conducted from May 2014 to January 2017 and included 38 consecutive inpatients with advanced cancer, who received tapentadol for the relief of severe pain. Patients with cancer pain that could not be controlled with other analgesics were included.
This study was approved by the Ethics Committee of Nagoya City University (approval no. 60 160 178).
Patients and methods
The inclusion criteria were as follows: Participants were cancer patients with neuropathic pain, who were at least 19 years old. Neuropathic pain was diagnosed using patient descriptions of pain quality, such as electric shocks, burning or coldness, 'pins and needles' sensations and numbness, as well as computed tomography by a palliative care physician or primary oncologist. Our diagnosis was because the range of pain is neuroanatomically effective and there are objective findings of sensory nerves (7) . Patients must have complained about the pain.
Switching procedure
We used tapentadol for patients diagnosed with neuropathic pain when the palliative care team intervened. The preswitching conversion ratio of tapentadol was fixed at 5:1 (oral equivalent tapentadol dose: oral oxycodone dose). The opioid used before switching was converted into oxycodone equivalents (8) . Previously used tramadol was replaced with tapentadol and then discontinued because the former was not effective against pain. Oxycodone and fentanyl were used in combination with tapentadol.
Data collection
Each patient underwent clinical assessment by at least one primary oncologist, the palliative care team's experienced full-time physician, nurse or pharmacist. The following data were collected for each patient 7 days before introducing tapentadol and 7 days after the end of titration of tapentadol: age, sex, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (9) prior to switching, primary tumor type, type and intensity of pain, primary opioids and their doses, primary oral tapentadol dose and number of rescue doses.
The Numerical Rating Scale (NRS) was used to assess the intensity of pain; NRS consists of 11 levels (0-10) (10). We defined 1-4 as mild pain, 5-6 as moderate pain, and 7-10 as severe pain (11) . Tapentadol is a sustained release drug. Therefore, it was necessary to evaluate how to control persistent pain. Since persistent pain is a pain lasting more than 12 h, one or two evaluations per day were inadequate. The NRS score was recorded several times daily and was the most frequently obtained number throughout the study period. We also investigated the type, dose and duration of use of other opioids that were prescribed before starting tapentadol.
Any potential adverse events were noted and classified using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03/ MedDRA/J v16.0.25 (12) .
Data analysis
All data are reported as means with 95% confidence intervals (CIs), ranges, medians, or frequencies (%), as appropriate. We used Welch's t-test to compare the means of the two populations, and the Wilcoxon signed-rank test to compare the dependent variables, pain intensity (NRS) and number of daily rescue doses. We used the Mann-Whitney U-test to test valid and invalid cases. A P value less than 0.05 was regarded as statistically significant, and all reported P values were two-tailed. Statistical procedures were conducted using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). Specifically, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics (13) .
Results
Patients
Thirty-eight patients underwent tapentadol switching in Nagoya City University Hospital. Sixteen patients were excluded because of medication refusal, medication intolerance, or the absence of neuropathic pain. Four patients did not take opioids before using tapentadol. Thus, 30 patients were enrolled in the study, and 18 patients completed the study. The mean morphine equivalent dose was 40.83 (range, 5-90) mg/day before tapentadol initiation and 61.94 (15-120) mg/day after titration [95% CI = −28.46 to −13.76; paired t(18) = −6.06; P < 0.01]. The mean tapentadol doses at the start and end of titration were 69.44 and 100.00 mg/day, respectively [95% CI = −55.98 to −5.12; paired t(18) = −2.54; P = 0.02]. Of the patients administered opioid before tapentadol use, five received tramadol, seven received oral oxycodone, two received transdermal fentanyl, and two received intravenous oxycodone. All of these opioids, except tramadol, were used in combination with tapentadol, until titration of tapentadol was complete.
Ten patients had analgesic adjuvant treatment before starting tapentadol (i.e. pregabalin, nine patients; duloxetine, one patient). One patient was prescribed pregabalin after starting tapentadol. There were no cases in which analgesic adjuvant or nonsteroidal anti-inflammatory drugs were discontinued or reduced. Cancer treatment was maintained consistently.
The reported numbers of patients with various neuropathic pain types were as follows: radiculopathic pain (5), malignant psoas syndrome (4), celiac plexus pain (4), peripheral nerve pain (3) and pains in different nerve plexuses (2). The following numbers of patients mentioned moderate to severe pain: radiculopathic pain (3), peripheral neuralgia (1) and pains in different nerve plexuses (1) . There was no patient with chemotherapy-induced peripheral neuropathy.
Pain and rescue
The NRS score after starting tapentadol tended to be lower than the NRS score before starting tapentadol (before 3.78, after 2.78; 95% CI −0.06 to 2.61; paired t(18) = 1.31: P = 0.20) (Fig. 1) .
The number of patients who had moderate or higher pain before starting tapentadol tended to decrease (before, six patients; after, three patients) (95% CI −0.41 to 7.74; paired t(5) = 2.31; P = 0.07) (Fig. 2) . Of the patients with moderate to severe pain, two switched from tramadol to tapentadol. Three patients received a combination therapy of oxycodone and tapentadol. The average number of rescues did not change from 3.8 to 3.25 (95% CI −0.50 to 1.72; paired t(14) = 1.2; P = 0.26). A severe side effect, defined as CTCAE > Grade 3, was found in one case of constipation. Other mild side effects, defined as CTCAE < Grade 2, were somnolence and gastrointestinal toxicity (Table 1) .
Drug costs per day were $5 at baseline and $8.1 after introduction (P < 0.05).
Responders and non-responders
We divided the patients into responders and non-responders. A responder was defined as a patient whose pain score improved by at least two points after tapentadol treatment (14, 15) . All other patients were defined as non-responders.
The morphine-equivalent daily dose used for responders and non-responders, respectively, before tapentadol administration was 44.6 ± 22.9 and 39.3 ± 24.9 (P = 0.65), and after administration was 74.1 ± 29.3 and 57.2 ± 33.6 (P = 0.53). The proportion of patients in the responder and non-responder groups, respectively, who had used opioids in the period before tapentadol initiation was 1/5 and 6/13 (P = 0.35) for 30 days, 0/5 and 4/13 (P = 0.19) for 30 −60 days, and 4/5 and 3/13 (P = 0.04) for ≥ 60 days. There was no difference in effectiveness between addition and switching ( Table 2) .
Discussion
The present study revealed the possibility that the effectiveness of tapentadol changes, depending on the periods of preceding opioid use. Tapentadol effectively reduced the intensity of moderate to severe pain in cancer patients with neuropathic pain; these patients had previously suffered from pain while taking analgesics that included narcotics.
Neuropathic pain, as defined by The International Association for the Study of Pain, is 'pain initiated or caused by a primary lesion in the nervous system (16) .' Factors that often cause or contribute to neuropathic pain include cancer, diabetes (17) , and side effects of chemotherapy. There are many reports on drug therapy for diabetic neuropathic pain, but there are few reports for cancer-related neuropathic pain (4, 5, 18) .
Although we could not confirm significant reductions in NRS scores, in the cases with moderate to severe pain corresponding to . After using tapentadol, the average pain of the patients tended to decrease, although there was no statistical difference (NRS before = 6, after = 3; 95% CI, −0.41 to 7.74; paired t(5) = 2.31, P = 0.07).
the inclusion criteria of past reports, a trend in NRS decline was observed. The decrease in NRS score is believed to be caused by the dual action mechanism of tapentadol. Neuropathic pain appears in 30-40% of cancer pain (19) , and the American Pain Society has indicated that it often coexists with nociceptive pain (20, 21) . Opioid μ analgesics are often used for nociceptive pain, while analgesic adjuvants, such as pregabalin, gabapentin and duloxetine, are used for neuropathic pain. Pregabalin and gabapentin produce their analgesic action by inhibiting the α2δ subunit of voltage-dependent calcium channels (22) . Duloxetine inhibits norepinephrine and serotonin uptake to induce analgesia (23) . The analgesic adjuvant used most frequently in our study was pregabalin, but there was one patient who used duloxetine. Tapentadol produces its pharmacological action through μ opioid receptor stimulation and inhibition of noradrenaline uptake, with the latter activity similar to that of duloxetine (24) .
Movement-related pain did not disappear with tapentadol. The performance status of our patients did not change after the introduction of tapentadol. Most patients were able to walk and care for themselves, and they were able to maintain activity even after starting tapentadol. However, we believe that rescue titration is necessary as prophylaxis and/or treatment, even if tapentadol is used.
Comparing responders and non-responders, there were no statistical differences in age, sex, body weight, primary tumor, switching from the previous opioid to tapentadol, and addition of tapentadol to the previous opioid. One non-responder used duloxetine. Seven patients used tramadol as a pretreatment, and all were switched to tapentadol. There was no significant difference in switching from tramadol to tapentadol. In contrast, Kress et al. reported the effectiveness of switching from tramadol to tapentadol, but their criteria for classifying patients as responders differed from those of ours (25) . Because we used tramadol and tapentadol not only for pain but also for numbness, most of the cases using tramadol in our study were less than 5 NRS before treatment.
Tapentadol was added when the preceding opioid was oxycodone or fentanyl. In this situation, there was also no statistical difference between switching and adding (25) . However, there were differences between responders and non-responders, depending on the premedication period of the opioid. Compared to oxycodone, tapentadol is regarded as an opioid analgesic with few side effects and fewer harmful side effects, such as gastrointestinal toxicity (26) .
We examined the possibility of combination therapy of two opioid analgesics. According to research by Mercadante et al., the addition of methadone or fentanyl to morphine, or morphine to fentanyl reduced pain intensity (27) . Lauretti et al. reported that the combined use of morphine and oxycodone reduced side effects (28) . Using tapentadol in addition to opioids, such as morphine, oxycodone and fentanyl, might have provided better analgesic effects because of the increased number of sites of action.
Side effects were mainly constipation, nausea, anorexia and somnolence, which were similar to those in the preceding report on chronic pain (25) . No new side effects were found with tapentadol used for neuropathic pain. We also observed a case of Grade 3 constipation, but this was considered a bad case of PS, with not only drugs but also long-term bed rest use considered as contributing factors. In Japan, 50 mg of tapentadol costs~1.8 dollars, while a 10 mg oxycodone extended-release tablet costs 2.3 dollars. In this study, the average dose of tapentadol after titration was 100 mg/day, which costs 3.7 dollars per day. An equivalent dose of oxycodone extended-release tablet would cost 4.7 dollars per day. This study was a before and after comparative study with no control group, so the economic effectiveness was not determined. Thus, it is possible that there are economic benefits to the use of tapentadol in combination with other opioids.
Regarding drug therapy for treatment of neuropathic pain, we have previously reported the effectiveness of methadone (29) . When using methadone in Japan, there is a limitation in that registration of a doctor, hospital or pharmacy is necessary (30) . There is no such requirement with Tapentadol. In that respect, tapentadol is highly versatile; this provides incentive to treat cancer-related neuropathic pain with tapentadol.
There are few reports that indicate whether a change in NRS is clinically effective. In this study, we examined cases with clinically effective changes in NRS. However, in our study the limitations included having a very small sample size and a single treatment group without a control. The possibility of cross resistance should also be taken into consideration. For further verification, it is necessary to conduct a prospective comparison study.
In conclusion, the results of this study suggest that tapentadol might be effective for cancer-related neuropathic pain to minimize the long-term use of first-line opioids. However, whether to increase the initial opioid or to add an analgesic adjuvant or tapentadol will need to be determined on a case-by-case basis.
